Shortly after, Ruxolitinib (INCB018424), a bioavailable JAK1/2 inhibitor, was reported to have similar mitigating effects on GVHD as IFNγR-/- T cells while the GvL effect was preserved (176, 177, 221, 222). The gene discussed is IFNGR1; the disease is graft versus host disease.